🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Leipzig
Clinical trial register · Germany

Clinical Trials in Leipzig, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5051 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5051
Studies in scope
all four open statuses
2882
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Berlin 1584 Hamburg 889 Essen 760 Dresden 707 Heidelberg 627
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca26 Eli Lilly and Company22 University of Leipzig21 Novartis Pharmaceuticals20 Janssen Research & Development, LLC17
Site location
Berlin1584 Hamburg889 Essen760 Dresden707 Heidelberg627
All 635 locations
Target enrolment
to

Trials with a site in Leipzig

511 of 5051 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Not yet open
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy
NCT07789483Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
DrugALXN2220
Alexion Pharmaceuticals, Inc.
Phase 3
1,180
Berlin, Hanover, Münster, Cologne, Homburg, Leipzig, Kiel, Essen
2027-11-23
Not yet open
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
NCT07335562Systemic Sclerosis
DrugsZola-cel·Nintedanib·Tocilizumab·Fludarabine
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
92
Berlin, Cologne, Erlangen, Leipzig, München, Tübingen, Würzburg
2027-02-03
Not yet open
Dalbavancin Therapy for Infective Endocarditis
NCT07699211Endocarditis Infective, Endocarditis, Bacterial
DrugDalbavancin administration
Stefan Hagel
Phase 3
184
Freiburg im Breisgau, Regensburg, Hamburg, Cologne, Leipzig, Berlin, Erfurt, Jena
2026-12
Not yet open
A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A
NCT07830732Haemophilia A
Novo Nordisk A/S
Phase 3
84
Berlin, Bonn, Hanover, Leipzig, Regensburg
2026-10-09
Not yet open
Routine Microaxial Heart Pump Support and Protocolized Pulmonary Artery Catheter Monitoring Versus Standard Care in Heart Attack-Related Cardiogenic Shock
NCT07762560Cardiogenic Shock, Acute Myocardial Infarction (AMI), Heart Failure, Acute
Leipzig Heart Science gGmbH
Not applicable
780
Leipzig
2026-10-01
Not yet open
External Beam Radiotherapy Combined With Endorectal High-dose-rate Brachytherapy in Elderly and Frail Patients With Rectal Cancer
NCT06729645Rectal Cancer
University Hospital of Cologne
Not applicable
80
Kempten, Frankfurt am Main, Cologne, Leipzig
2026-09-30
Recruiting
Hyperspectral Imaging in Robot-Assisted Partial Nephrectomy
NCT07803315Kidney Neoplasm, Renal Mass up to 7cm
University of Leipzig
Observational
60
Leipzig
2026-09-01
Recruiting
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
NCT07743463Obesity, Overweight, Chronic Weight Management
DrugASC30 A1
Ascletis Pharma (China) Co., Limited
Phase 3
3,003
Berlin, Essen, Hanover, Leipzig
2026-08-31
Recruiting
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
NCT07794579Overweight, Prediabetic State, Prehypertension, Obesity, Abdominal
DrugOrforglipron
Eli Lilly and Company
Phase 3
2,001
Berlin, Bochum, Hanover, Hohenmölsen, Karlsruhe, Leipzig, Obertshausen, Offenbach
2026-08-26
Not yet open
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
NCT07735637Newly Diagnosed Multiple Myeloma (NDMM)
DrugsASCT·AZD0120·Melphalan·Lenalidomide
AstraZeneca
Phase 3
750
Berlin, Dresden, Essen, Freiburg im Breisgau, Hamburg, Leipzig, München, Oldenburg
2026-08-25
Recruiting
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
NCT07797335Type 2 Diabetes, Cardiovascular Risk
DrugZenagamtide
Novo Nordisk A/S
Phase 3
1,778
Deggingen, Essen, Gelnhausen, Hamburg, Hohenmölsen, Jerichow, Leipzig, Ratingen
2026-08-24
Recruiting
PULSed Field Ablation for Atrial Fibrillation Using a Balloon for Early Intervention - Study
NCT07621003Atrial Fibrillation
Asklepios proresearch
Not applicable
264
Bad Oeynhausen, Cologne, Düsseldorf, Frankfurt, Giessen, Hamburg, Herne, Leipzig
2026-08-19
Recruiting
A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.
NCT07619131Hypercholesterolaemia
DrugsRosuvastatin 1·Rosuvastatin 2
AstraZeneca
Phase 3
600
Ahrensburg, Berlin, Bochum, Gladbeck, Hamburg, Hanover, Karlsruhe, Leipzig
2026-08-12
Recruiting
A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT07759245Pulmonary Disease, Chronic Obstructive
DrugBrenipatide
Eli Lilly and Company
Phase 2
606
Frankfurt, Hamburg, Landsberg am Lech, Leipzig, Mainz, Rheine
2026-08-07
Not yet open
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
NCT07775300Depressive Disorder, Major
DrugBrenipatide
Eli Lilly and Company
Phase 3
1,000
Berlin, Chemnitz, Hamburg, Leipzig, Schwerin
2026-08
Not yet open
Master Study Protocol for the Cohort of the Specialist Network Stroke (SN Stroke)(Stroke-CORE)
NCT07553650Intracerebral Haemorrhage, Paediatric Stroke, Stroke Acute, Stroke
Charite University, Berlin, Germany
Observational
12,750
Hamburg, Berlin, Bielefeld, Dresden, Erlangen, Essen, Heidelberg, Leipzig
2026-07-27
Recruiting
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
NCT07492680Solid Tumors
DrugsNavlimetostat·Pumitamig·Temozolomide·Cetuximab
Bristol-Myers Squibb
Phase 2
260
Mainz, Hamburg, Heidelberg, Leipzig, München, Würzburg
2026-07-27
Not yet open
CRP Apheresis in Infarct-Related Cardiogenic Shock
NCT07687017Cardiogenic Shock, Acute Myocardial Infarction (AMI)
Leipzig Heart Science gGmbH
Not applicable
50
Leipzig
2026-07-20
Recruiting
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
NCT07667803Weight Management
DrugElecoglipron
AstraZeneca
Phase 3
4,500
Bad Oeynhausen, Bochum, Cologne, Dresden, Falkensee, Gera, Hamburg, Leipzig
2026-06-29
Recruiting
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
NCT07764978Newly Diagnosed Multiple Myeloma
DrugsAZD0120·Isatuximab·Bortezomib·Daratumumab
AstraZeneca
Phase 3
750
Berlin, Cologne, Dresden, Essen, Freiburg im Breisgau, Hamburg, Kiel, Leipzig
2026-06-26
Recruiting
An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly
NCT07583563Acromegaly
Camurus AB
Observational
200
Aachen, Leipzig, Magdeburg, München, Würzburg
2026-06-05
Recruiting
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
NCT07498426Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Novartis Pharmaceuticals
Phase 3
300
Munich, Würzburg, Bonn, Düsseldorf, Dresden, Leipzig, Beelitz, Berlin
2026-06-03
Not yet open
A Study of Barrett's Esophagus Patients: Optimization of a Risk Model to Better Predict the Development of Cancer Recurrence and the Effect of Risk Profile Disclosure on Patient Quality of Life and Fear of Cancer
NCT07455422Barrett Esophagus, Barrett Esophagus Adenocarcinoma, Adenocarcinoma - GEJ, Gastroenterology
University Hospital, Antwerp
Not applicable
266
Leipzig
2026-06-01
Recruiting
A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis
NCT07470879Colitis, Ulcerative
DrugEtrasimod
Pfizer
Phase 2
24
Münster, Leipzig, Tübingen, Wuppertal
2026-05-28
Recruiting
A Study in Children and, Adults With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Treated With Adzynma
NCT07353099Thrombotic Thrombocytopenic Purpura (TTP)
Takeda
Observational
50
Bonn, Cologne, Jena, Leipzig, München
2026-05-26
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07577856Colitis, Ulcerative
DrugsJNJ-78934804·Tremfya·Guselkumab
Janssen Research & Development, LLC
Phase 3
644
Berlin, Dresden, Hanover, Kiel, Leipzig, Mannheim, Rostock
2026-05-23
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
NCT07577843Crohn Disease
DrugsJNJ-78934804·Tremfya·Guselkumab
Janssen Research & Development, LLC
Phase 3
460
Berlin, Dresden, Hanover, Kiel, Leipzig, Mannheim, Rostock
2026-05-22
Recruiting
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)
NCT07545759Irritable Bowel Syndrome, Diarrhea
DrugBrenipatide
Eli Lilly and Company
Phase 2
531
Berlin, Dachau, Hamburg, Karlsruhe, Leipzig, Offenbach
2026-05-06
Recruiting
Glycolytic Phenotype (vLapeak) and Magnitude of Skeletal Muscle Hypertrophy After Resistance Training
NCT07721766Healthy Volunteers, Muscle Hypertrophy, Glycolysis, Moderately Trainend
Technical University of Munich
Not applicable
120
München, Cologne, Düsseldorf, Chemnitz, Leipzig
2026-05-04
Not yet open
Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues
NCT07074782Glaucoma
Association for Innovation and Biomedical Research on Light and Image
Observational
1,500
Bonn, Leipzig
2026-05
Active, closed
AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss
NCT07503210Obesity
DrugNNC0487-0111
Novo Nordisk A/S
Phase 3
606
Speyer, Hamburg, Leipzig, Lingen, Münster, Oldenburg in Holstein, Saint Ingbert-Oberwürzbach
2026-04-21
Recruiting
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
NCT07355218Systematic Lupus Erythematosus, Cutaneous Lupus Erythematosus
DrugEnpatoran
EMD Serono Research & Development Institute, Inc.
Phase 3
202
Wuppertal, Leipzig
2026-04-01
Recruiting
Effects of a 6-months Fiber- and Polyphenol-rich Diet on Brain Inflammatory Processes in Perimenopausal Women Living With Overweight or Obesity
NCT07501377Overweight and/or Obesity, Perimenopausal Women
Max Planck Institute for Human Cognitive and Brain Sciences
Not applicable
120
Leipzig
2026-03-19
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
NCT07221149Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
DrugsPumitamig·Folfox·Nivolumab
Bristol-Myers Squibb
Phase 2/3
690
Berlin, Frankfurt, Hamburg, Heidelberg, Leipzig, Mainz, Mannheim, Ulm
2026-03-13
Recruiting
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
NCT07438496Lupus Erythematosus, Systemic
DrugNipocalimab
Janssen Research & Development, LLC
Phase 3
600
Dresden, Heidelberg, Leipzig, Meerbusch, München
2026-03-05
Recruiting
Efficacy and Safety of Oral Controlled-release Nicotinic Acid (CIR-NA) for the Remission of Prediabetes. (CONCEPT)
NCT07286747Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)
University Hospital Schleswig-Holstein
Phase 2
390
Berlin, Kiel, Leipzig, Lübeck, München, Tübingen
2026-03-03
Not yet open
Multicentric Approval Study Trans-Duodenal Barrier for Typ 2 Diabetes With Obesity
NCT07417683Typ 2 Diabetes, Obesity, Obesity Type 2 Diabetes Mellitus, MASH
Trans-Duodenal Concepts GmbH
Not applicable
126
Mannheim, Bamberg, Würzburg, Bochum, Dresden, Leipzig, Berlin
2026-03
Active, closed
A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)
NCT07400653Obesity, Overweight and/or Obesity, Overweight, Diabetes, Type 2
DrugBerobenatide
Pfizer
Phase 3
1,078
Munich, Leipzig, Berlin, Dresden, Essen, Hamburg, Holstein, Karlsruhe
2026-02-24
Recruiting
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
NCT07391657Relapsed Refractory Multiple Myeloma
DrugsDarzalex·AZD0120·Velcade·Carfilzomib
AstraZeneca
Phase 3
508
Berlin, Dresden, Erlangen, Essen, Freiburg im Breisgau, Hamburg, Leipzig, Mainz
2026-02-23
Recruiting
Clinical Performance and Safety Assessment of the Use of iCover Balloon Expandable Covered Stent (iVascular) Implanted as Bridging Stent in FEVAR (Fenestrated Endovascular Aortic Repair) for the Treatment of Complex Abdominal Aortic Aneurysms
NCT07529275Complex Abdominal Aortic Aneurysms
iVascular S.L.U.
Not applicable
165
Cologne, Hamburg, Leipzig, München
2026-02-16
Recruiting
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
NCT07220083Focal Segmental Glomerulosclerosis
DrugApecotrep
Boehringer Ingelheim
Phase 3
286
Berlin, Cologne, Hamburg, Hanover, Heidelberg, Leipzig, Mainz, Würzburg
2026-02-16
Recruiting
Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS
NCT07197944Short Bowel Syndrome
DrugGlepaglutide
Zealand Pharma
Phase 3
90
Rostock, Leipzig, Aachen, Berlin, Bonn, Hamburg
2026-02-11
Recruiting
A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.
NCT07215702Sepsis, Acute Kidney Injury
DrugAZD4144
AstraZeneca
Phase 2
124
Aachen, Essen, Frankfurt, Greifswald, Heidelberg, Kiel, Leipzig, Münster
2026-02-10
Recruiting
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
NCT07353931Osteoarthritis, Overweight or Obesity
DrugEloralintide
Eli Lilly and Company
Phase 3
900
Bochum, Bünde, Duisburg, Hamburg, Karlsruhe, Leipzig, München, Offenbach
2026-02-09
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
NCT07321886Obesity, Overweight
DrugEloralintide
Eli Lilly and Company
Phase 3
1,980
Cologne, Dresden, Duisburg, Essen, Hamburg, Leipzig, Lingen, Mainz
2026-02-06
Recruiting
A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma
NCT07323654Eosinophilic Asthma
DrugKT-621
Kymera Therapeutics, Inc.
Phase 2
264
Berlin, Leipzig
2026-01-28
Recruiting
Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis
NCT07332091Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis
CSL Behring
Phase 2
84
Freiburg im Breisgau, Heidelberg, Leipzig, Weinheim
2026-01-22
Recruiting
Beeline: A Phase 3 Study in GRIN-related Neurodevelopmental Disorder
NCT07224581GRIN-related Neurodevelopmental Disorder
DrugRadiprodil
GRIN Therapeutics, Inc.
Phase 3
100
Greifswald, Leipzig
2026-01-05
Active, closed
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
NCT07277660Atopic Dermatitis
DrugGalvokimig
UCB Biopharma SRL
Phase 2
165
Bad Bentheim, Leipzig, Mahlow
2025-12-29
Active, closed
Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
NCT07311850Obesity and Overweight
DrugBerobenatide
Pfizer
Phase 3
3,578
Munich, Leipzig, Bad Homburg, Berlin, Cologne, Dresden, Essen, Hamburg
2025-12-19
Recruiting
Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
NCT07284875Obesity, Overweight
DrugRibupatide
Kailera
Phase 3
2,340
Tübingen, Falkensee, Cologne, Essen, Dresden, Leipzig, Oldenburg in Holstein, Hamburg
2025-12-18
Recruiting
Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma
NCT07301736Asthma
Chiesi Farmaceutici S.p.A.
Phase 2
780
Ahrensburg, Berlin, Cottbus, Delitzsch, Düsseldorf, Hamburg, Ibbenbueren, Leipzig
2025-12-17
Recruiting
Trifluridine/Tipiracil + Fruquintinib Versus Trifluridine/Tipiracil Alone for Metastatic Oeso-gastric Adenocarcinoma
NCT07270991Metastatic Oesogastric Adenocarcinoma
DrugsTrifluridine/Tipiracil·Fruquintinib
Federation Francophone de Cancerologie Digestive
Phase 3
324
Chemnitz, Essen, Frankfurt, Hamburg, Jena, Leipzig, München, Rostock
2025-12-15
Recruiting
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
NCT07221188Non-alcoholic Fatty Liver Disease
DrugEfimosfermin alfa
GlaxoSmithKline
Phase 3
1,250
Leipzig
2025-12-12
Recruiting
A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma
NCT07059299Esophagogastric Junction Adenocarcinoma, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Resectable Esophagogastric Adenocarcinoma
DrugTislelizumab
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 1
18
Frankfurt, Hamburg, Leipzig, München
2025-12-12
Recruiting
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
NCT07222800Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site
DrugsPF-08634404·Avastin·Bevacizumab
Pfizer
Phase 3
800
Frankfurt am Main, Leipzig, Berlin, Dresden, Hamburg, München
2025-12-11
Recruiting
Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody
NCT07285213Clostridioides Difficile Infection
AstraZeneca
Phase 2
230
Augsburg, Berlin, Cologne, Frankfurt, Hamburg, Jena, Leipzig, München
2025-12-10
Recruiting
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
NCT07224373Multiple Sclerosis
AstraZeneca
Phase 1
24
Leipzig, Magdeburg, Würzburg
2025-12-09
Recruiting
Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure
NCT07038356Acute Decompensated Heart Failure (ADHF)
DrugDapagliflozin
Christian Schulze
Phase 3
536
Jena, Bad Nauheim, Berlin, Bonn, Dresden, Göttingen, Halle, Leipzig
2025-12-08
Recruiting
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
NCT07209111Neoplasm Malignant
DrugsCalderasib·Cetuximab
Merck Sharp & Dohme LLC
Phase 2
150
Leipzig, Jena, Berlin
2025-12-04
Recruiting
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
NCT07276399Squamous Cell Carcinoma of Head and Neck
DrugsAmivantamab·Cisplatin·Carboplatin·Pembrolizumab
Janssen Research & Development, LLC
Phase 3
500
Bonn, Essen, Frankfurt, Giessen, Hanover, Leipzig, Regensburg, Rostock
2025-12-03
Recruiting
Early Detection and IntervenTion in Heart Failure
NCT07731490Heart Failure (HF)
University Hospital, Basel, Switzerland
Not applicable
18,000
Freiburg im Breisgau, Herne, Leipzig
2025-12-03
Recruiting
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)
NCT07276724Severe Asthma
DrugGB-0895
Generate Biomedicines
Phase 3
786
Deggingen, München, Frankfurt am Main, Witten, Leipzig, Lübeck, Berlin
2025-12-03
Recruiting
Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice
NCT07302802Monogenic Obesity
DrugSemaglutide
Prof. Dr. Martin Wabitsch
Observational
70
Berlin, Leipzig, Ulm
2025-12-01
Recruiting
Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis
NCT07236099Prurigo Nodularis (PN)
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2
135
Berlin, Darmstadt, Leipzig, Mainz
2025-11-27
Recruiting
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
NCT06804811NonSegmental Vitiligo
DrugRuxolitinib
Incyte Corporation
Phase 3
250
Berlin, Erlangen, Hamburg, Kiel, Leipzig, Mainz, München, Münster
2025-11-13
Active, closed
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07170150Alzheimers Disease
DrugTrontinemab
Hoffmann-La Roche
Phase 3
1,060
Erlangen, Berlin, Bonn, Cologne, Dresden, Homburg/Saar, Jena, Leipzig
2025-11-12
Recruiting
REpeat Intervention For Failed Surgical BioProsthEtic AorTic Valves (REPEAT)
NCT07462624Degenerative Aortic Valve Disease
Heart Center Leipzig - University Hospital
Not applicable
890
Leipzig
2025-11-10
Recruiting
A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation
NCT06243731Cytomegalovirus (CMV), Kidney Disease, Kidney Failure
Takeda
Observational
10
Würzburg, Leipzig
2025-11-03
Recruiting
A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
NCT07287644Hidradenitis Suppurativa (HS)
DrugBFB759
Bluefin Biomedicine, Inc.
Phase 2/3
210
Bochum, Frankfurt, Heidelberg, Leipzig, Lübeck, Munich
2025-11-03
Recruiting
A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.
NCT07219615Chronic Spontaneous Urticaria
DrugsLitfulo·Ritlecitinib
Pfizer
Phase 2
200
Stuttgart, Münster, Berlin, Dresden, Leipzig, Wuppertal
2025-10-30
Recruiting
Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
NCT07007962Immune Thrombocytopenia
DrugRilzabrutinib
Sanofi
Phase 3
60
Leipzig
2025-10-24
Recruiting
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
NCT07219173Asthma
DrugBrenipatide
Eli Lilly and Company
Phase 2
531
Bendorf, Berlin, Essen, Frankfurt, Hamburg, Leipzig, Mainz, Offenbach
2025-10-22
Recruiting
A Non-interventional Study of Participants With BPDCN Treated With Chemotherapy
NCT07785180Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Stemline Therapeutics, Inc.
Observational
140
Bremen, Chemnitz, Leipzig, Lübeck, Munich, Oldenburg, Würzburg
2025-10-17
Recruiting
EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)
NCT06997588PIK3CA-related Overgrowth Spectrum (PROS)
DrugAlpelisib
Novartis Pharmaceuticals
Phase 2
104
Freiburg im Breisgau, Düsseldorf, Leipzig, Halle, Berlin, Stuttgart
2025-10-09
Recruiting
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07184996Ulcerative Colitis
DrugDuvakitug
Sanofi
Phase 3
980
Berlin, Herne, Kiel, Leipzig, Minden, Ulm
2025-10-08
Recruiting
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
NCT07196722Crohn Disease
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 2/3
1,092
Berlin, Dachau, Erlangen, Halle, Hanover, Jerichow, Kiel, Leipzig
2025-10-03
Recruiting
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
NCT06989437Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma
DrugPonsegromab
Pfizer
Phase 2/3
982
München, Düsseldorf, Dresden, Leipzig, Berlin
2025-10-03
Recruiting
Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes
NCT07102628Acute Coronary Syndrome
DrugInclisiran
Novartis Pharmaceuticals
Phase 3
300
Leipzig, Coburg, Erfurt, Essen, Hennigsdorf, Kiel
2025-10-03
Recruiting
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
NCT07184931Crohn's Disease
DrugDuvakitug
Sanofi
Phase 3
980
Tübingen, Ulm, Würzburg, Remscheid, Ludwigshafen am Rhein, Dresden, Leipzig, Jerichow
2025-10-01
Recruiting
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
NCT07204275Primary Membranous Nephropathy
DrugsPovetacicept·Tacrolimus
Vertex Pharmaceuticals Incorporated
Phase 2/3
176
Allemagne, Leipzig, Würzburg
2025-09-30
Recruiting
A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis
NCT06865417Ulcerative Colitis
DrugFilgotinib
Alfasigma S.p.A.
Phase 3
80
Aachen, Leipzig, Mainz, Tübingen
2025-09-29
Recruiting
Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With Uncontrolled Hypertension
NCT07115953Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases
Medtronic Vascular
Not applicable
130
Homburg, Lübeck, Erlangen, Leipzig, Villingen-Schwenningen
2025-09-22
Recruiting
Impella Pump Return Study to Analyze Deposits and Biomaterial in Used Pumps
NCT06765226Heart Failure
Abiomed Inc.
Observational
200
Heidelberg, Düsseldorf, Dresden, Leipzig, Berlin, Cologne, Essen
2025-09-21
Recruiting
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
NCT07190209Chronic Obstructive Pulmonary Disease
DrugLunsekimig
Sanofi
Phase 3
942
Ahrensburg, Augsburg, Berlin, Darmstadt, Frankfurt, Frankfurt am Main, Hamburg, Leipzig
2025-09-16
Recruiting
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
NCT07153471Osteoarthritis
DrugOrforglipron
Eli Lilly and Company
Phase 3
800
Bochum, Dresden, Hamburg, Hanover, Karlsruhe, Leipzig, München, Offenbach
2025-09-15
Active, closed
A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)
NCT07037875GERD (Gastroesophageal Reflux Disease)
DrugsLinaprazan glurate·Lansoprazole
Cinclus Pharma Holding AB
Phase 3
500
Mannheim, Dachau, Munich, Leipzig
2025-09-11
Recruiting
Validation of Energy Expenditure Measures Study
NCT07155564Obesity Prevention, Healthy
University of Leipzig
Observational
49
Leipzig
2025-08-26
Recruiting
Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) Patients
NCT06981325Basal Cell Carcinoma (BCC), First Line Treatment
DrugCemiplimab
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
34
Erfurt, Erlangen, Heidelberg, Leipzig, Minden, Oberhausen, Tübingen
2025-08-07
Recruiting
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
NCT07088068Type 1 Diabetes Mellitus
DrugTeplizumab
Sanofi
Phase 3
723
Augsburg, Bielefeld, Dresden, Frankfurt, Freiburg im Breisgau, Hanover, Leipzig, Munich
2025-08-06
Recruiting
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease
NCT06607458Refractory Metastatic Colorectal Cancer
DrugsMelphalan·Trifluridine/Tipiracil·Bevacizumab
Delcath Systems Inc.
Phase 2
90
Hanover, Leipzig
2025-08-05
Recruiting
Harmony TPV EMEA PMS
NCT06906926Severe Pulmonary Valve Regurgitation
Medtronic Cardiovascular
Not applicable
80
Bad Oeynhausen, Berlin, Leipzig, Munich
2025-07-30
Active, closed
Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma
NCT07120503Asthma (Diagnosis)
DrugWIN378
Windward Bio
Phase 2
136
Berlin, München, Bendorf, Lübeck, Darmstadt, Frankfurt am Main, Leipzig, Mainz
2025-07-24
Recruiting
A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE)
NCT07001280Hereditary Angioedemas
CSL Behring
Observational
200
Ulm, Frankfurt am Main, Hanover, Leipzig, Hamburg, Berlin
2025-07-21
Recruiting
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
NCT06570798Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis
DrugsUplizna·Inebilizumab·Blinatumomab
Amgen
Phase 2
220
Cologne, Düsseldorf, Leipzig, München
2025-07-16
Active, closed
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
NCT07015983Lupus Erythematosus, Systemic, Lupus Nephritis
DrugsZola-cel·Fludarabine·Cyclophosphamide
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
89
Leipzig, Magdeburg, Berlin, Cologne, Erlangen, Herne
2025-07-14
Recruiting
A Phase 1b/2a Trial to Evaluate Invobenitug Also Known as Procizumab (PCZ; AK1967) in Critical Cardiovascular Care.
NCT06832722Shock, Cardiogenic
4TEEN4 Pharmaceuticals GmbH
Phase 1/2
90
Berlin, Freiburg im Breisgau, Hamburg, Leipzig, Mannheim
2025-07-13
Recruiting
Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With Metastatic or Locally Advanced PDAC
NCT07145450PDAC
Anocca AB
Phase 1/2
96
Berlin, Dresden, Heidelberg, Leipzig, München, Tübingen
2025-07-03
Recruiting
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT07052903Transthyretin Amyloidosis With Cardiomyopathy
DrugNucresiran
Alnylam Pharmaceuticals
Phase 3
1,750
Berlin, Cologne, Dresden, Göttingen, Hanover, Heidelberg, Leipzig, Magdeburg
2025-07-02
Active, closed
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
NCT06966453Breast Cancer, Breast Neoplasms
DrugDisitamab Vedotin
Pfizer
Phase 1/2
74
Essen, Dresden, Berlin, Leipzig
2025-06-30
Rows per page Showing 1–100 of 511
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 29 September 2026. https://priyalifescience.com/clinical-trials-germany/city/leipzig

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,051 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 511 of those studies with a site in Leipzig.

How many clinical trials are recruiting in Leipzig?

251 of the 511 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 14 have not yet opened recruitment, 239 are active but closed to new participants, and 7 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Leipzig), 511 studies
PhaseStudiesRecruitingShare
Phase 31988138.7%
Observational925518%
Not applicable834416.2%
Phase 2813915.9%
Phase 1/226155.1%
Phase 2/316113.1%
Phase 11142.2%
Phase 4420.8%

Most active sponsors

Lead sponsors with the most studies (Leipzig)
Lead sponsorStudiesRecruiting
AstraZeneca2612
Eli Lilly and Company2211
University of Leipzig2114
Novartis Pharmaceuticals208
Janssen Research & Development, LLC1710
Pfizer134
Sanofi115
Bristol-Myers Squibb95
GlaxoSmithKline94
AbbVie80
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.